Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

In this work, we aim to evaluate the hypothesis that the definition of functional vitamin D deficiency is able to identify individuals who significantly benefit from vitamin D supplementation.

Source: 1. Introduction. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Multiple reported designs.

Multiple reported designs

More than one design is explicitly reported; examine the supporting methods.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Classification of Vitamin D Status Based on Vitamin D Metabolism: A Randomized Controlled Trial in Hypertensive Patients

Source: Article title.

The Styrian Vitamin D Hypertension Study is a double-blind, placebo-controlled trial in 200 hypertensive patients with serum 25(OH)D below 75 nmol/L from the Department of Internal Medicine of the Medical University of Graz.

Source: Methods.

In total, 518 study participants were screened for this study (of whom 200 were included in the RCT) and are thus part of the entire study cohort termed Styrian Hypertension Study.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Classification of Vitamin D Status Based on Vitamin D Metabolism: A Randomized Controlled Trial in Hypertensive Patients

Multiple reported designs · Nutrients · 2024

Original publication title

Classification of Vitamin D Status Based on Vitamin D Metabolism: A Randomized Controlled Trial in Hypertensive Patients

Sieglinde Zelzer; Andreas Meinitzer; Dietmar Enko; Martin H. Keppel; Markus Herrmann; Verena Theiler-Schwetz; Christian Trummer; Lisa Schmitt; Andreas Tomaschitz; Patrick Sadoghi; Jutta Dierkes; Pawel Pludowski; Armin Zittermann; Winfried März; Stefan Pilz

© 2024 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In conclusion, our criteria for functional vitamin D deficiency did not show that vitamin D-deficient patients significantly benefit from vitamin D supplementation regarding bone markers and cardiovascular risk factors, except for a decrease in PTH and expected changes in vitamin D metabolites. Further studies, in particular large RCTs, are warranted to explore whether the measurements of vitamin D metabolites in addition to 25(OH)D are useful for the classification of vitamin D status and identification of individuals who particularly benefit from vitamin D treatment.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

There exists a wide consensus that the assessment of vitamin D status is performed by measuring serum 25-hydroxyvitamin D (25(OH)D) concentrations [1,2]. An ongoing scientific controversy prevails regarding the precise 25(OH)D cut-offs for defining vitamin D deficiency and sufficiency [1,3,4]. Due to unknown reasons, vitamin D requirements seem to be met at extremely low serum 25(OH)D concentrations for some individuals, whereas others require higher serum 25(OH)D levels to satisfy their vitamin D needs [3,5,6,7,8].

Measuring 24,25-dihydroxyvitamin D (24,25(OH)2D) in addition to 25(OH)D and calculating the vitamin D metabolite ratio (VMR) out of these two molecules (i.e., 24,25(OH)2D divided by 25(OH)D) may serve as an indicator of “functional vitamin D deficiency” that may overcome some of the limitations of exclusively measuring serum 25(OH)D for vitamin D status assessment [9]. The basic concept behind this approach is that the hydroxylation of 25(OH)D to 24,25(OH)2D is considered the first step in the catabolism of vitamin D.

Assuming that the human body regulates, at least in part, vitamin D metabolism according to the individual demands, a lower catabolism, and thus lower relative concentration of 24,25(OH)2D and a subsequently lower VMR, may hypothetically indicate a higher vitamin D requirement and vice versa [9] (see Figure 1).

There is still no established consensus regarding a universal definition of functional vitamin D deficiency, but based on previous reports, we classify functional vitamin D deficiency in individuals with 25(OH)D below 50 nmol/L (multiplied by 2.496 to convert ng/mL to nmol/L), 24,25(OH)2D below 3 nmol/L and a VMR of less than 4% [9].

Controversial data exist on whether VMR predicts increases in 25(OH)D after vitamin D supplementation, with a previous investigation of our group failing to document such an effect [10]. By contrast, some studies have already suggested that assessment of vitamin D status by using the VMR for defining functional vitamin D deficiency may provide useful information in addition to serum 25(OH)D alone [9,11,12,13,14,15]. In this context, better characterization of bone health and mortality risk has been reported for this approach as opposed to conventional vitamin D status assessment [9,13,15].

Data on this issue are, however, limited to only a few studies, and there exists a knowledge gap regarding randomized controlled trials (RCTs) evaluating clinically relevant vitamin D effects in persons with functional vitamin D deficiency.

In this work, we aim to evaluate the hypothesis that the definition of functional vitamin D deficiency is able to identify individuals who significantly benefit from vitamin D supplementation. This study is a post hoc analysis of the Styrian Vitamin D Hypertension Study, an RCT in 200 hypertensive patients with low 25(OH)D, on vitamin D supplementation with 2.800 international units (IU) (50 µg) daily for 8 weeks [16]. In individuals with serum 25(OH)D concentrations below 50 nmol/L, we evaluate, as our primary outcome analyses, whether those with functional vitamin D deficiency significantly benefit from vitamin D supplementation concerning markers of bone metabolism and cardiovascular risk.

In addition, we evaluate in cross-sectional analyses whether individuals with and without functional vitamin D deficiency differ with regard to various clinical and laboratory characteristics.

Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction

Study methods

What methods does the paper describe?

2.1. Study Design

The Styrian Vitamin D Hypertension Study is a double-blind, placebo-controlled trial in 200 hypertensive patients with serum 25(OH)D below 75 nmol/L from the Department of Internal Medicine of the Medical University of Graz. In total, 518 study participants were screened for this study (of whom 200 were included in the RCT) and are thus part of the entire study cohort termed Styrian Hypertension Study. The main objective of the initial trial was to evaluate whether vitamin D supplementation with 2.800 international units (IU) daily for 8 weeks reduces 24 h systolic ambulatory blood pressure (ABP) compared to placebo.

Secondary endpoints included 24 h diastolic ABP and other cardiovascular risk factors. All study participants gave written informed consent, and the ethics committee at the Medical University of Graz, Austria, approved the initial study and the additional analyses of this present post hoc analysis. The study was registered at EU Clinical Trials Register (http://www.clinicaltrialsregister.eu (accessed on 23 February 2024), EudraCT number 2009-018125-70) and at clinicaltrials.gov (ClinicalTrials.gov Identifier NCT02136771). The publications of this RCT adhere to the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement.

Further details on the study methods and the main study findings of this RCT were published elsewhere [16]. For the current investigation, we included only individuals with available data to calculate the VMR, i.e., data on 25(OH)D and 24,25(OH)2D.

2.2. Laboratory Measurements

In serum samples that were stored at −80° Celsius from blood collection until analysis in October 2023, 25(OH)D and 24,25(OH)2D were determined by a validated LC-MS/MS method that is regularly evaluated by internal and external quality controls with satisfactory results [17]. For external quality assessment, this method is enrolled in the Vitamin D External Quality Assessment Scheme (DEQAS) that uses target values assigned by the Centers for Disease Control and Prevention (CDC) reference measurement procedure (i.e., certified reference material (SRM 2972a) from the National Institute of Standards and Technology (NIST)).

For all vitamin D metabolites, the intra: and inter-day imprecision was <9% and <12%, respectively, and the limit of detection (LOD) and limit of quantification (LOQ) ranged from 0.12 to 0.60 ng/mL (0.3 to 1.5 nmol/L) and 0.40 to 1.24 ng/mL (1.0 to 3.1 nmol/L), respectively. Recovery varied between 76.1% and 84.3%. Regarding bone markers, β-CrossLaps (CTX), osteocalcin and procollagen type 1 amino-terminal propetide (P1NP) were determined by electrochemiluminescence immunoassays (Roche Diagnostics, Mannheim, Germany) according to manufacturers’ instructions. Bone-specific alkaline phosphatase (bALP) was measured by a spectrophotometric immunoassay (Immunodiagnostic Systems Ltd., Boldon, UK). 1,25-dihydroxyvitamin D (1,25(OH)2D) concentrations were determined by a chemoluminescence immunoassay (Immunodiagnostic Systems Ltd., Boldon, UK) and C-terminal fibroblast growth factor-23 (FGF-23) by a multi matrix ELISA (BIOMEDICA Medizinprodukte GmbH & CO KG, Vienna, Austria).

In addition to vitamin D metabolites and bone markers, several other laboratory parameters were determined by methods that have been described elsewhere [16].

2.3. Outcome Measures

All primary and secondary outcome measures of the initial RCT were re-analyzed as part of this investigation. In addition, for analyses on bone and mineral metabolism, we also included 24,25(OH)2D, VMR, 1,25(OH)2D, FGF-23, bALP, CTX, osteocalcin and P1NP.

2.4. Statistical Analyses

Continuous data with a normal distribution are shown as means with standard deviation (SD), and non-normally distributed variables are shown as medians with 25th to 75th percentile. Categorical variables are presented as percentages. Non-normally distributed variables are log(e)-transformed before use in parametric procedures. Group comparisons of individuals with and without functional vitamin D deficiency are performed by Chi-Square test and Student’s t test. In individuals with functional vitamin D deficiency, analysis of co-variance (ANCOVA) with adjustment for baseline values is used to test for differences between the vitamin D and the placebo group.

No data imputation was performed for missing values. All analyses are exploratory for these post hoc analyses. A power calculation revealed that the expected sample sizes for our subgroup analyses in participants with functional vitamin D deficiency seem reasonable for most outcomes studied. For example, for the primary outcome measure of the initial RCT publication, i.e., 24 h systolic ABP, we calculated, with a power of 80% and an α of 0.05, a sample size of 22 participants per study group (44 participants overall) when assuming an effect size of 8 mm Hg and an SD of 9 mm Hg.

A p-value below 0.05 was considered statistically significant. Statistical analyses were performed by using SPSS Version 27 (SPS, Chicago, IL, USA).

Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods

Discussion

In vitamin D-deficient hypertensive patients, those with functional vitamin D deficiency did not yield significant benefits in response to vitamin D supplementation with regard to markers of bone health and cardiovascular risk except for a decrease in PTH concentrations and expected changes in vitamin D metabolites. Cross-sectional analyses in vitamin D-deficient individuals showed, amongst others, a significantly higher prevalence of diabetes mellitus and disturbed glucose metabolism in those with versus without functional vitamin D deficiency.

Our study is, to the best of our knowledge, the first to evaluate whether individuals with “functional vitamin D deficiency” significantly benefit from vitamin D supplementation regarding markers of bone health and cardiovascular risk. As in our initial publication of this RCT, we did not detect significant benefits of vitamin D supplementation apart from well-established effects on PTH and expected changes in vitamin D metabolites. Our work was stimulated by previous observational data suggesting that individuals with functional vitamin D deficiency, i.e., those with relatively low 24,25(OH)2D concentrations and a low VMR, had adverse bone health and higher mortality risk as compared to individuals with an unremarkable vitamin D profile [9,13,15].

In this context, we could not confirm the findings derived from other cohorts that individuals with functional vitamin D deficiency had an adverse profile regarding bone turnover markers [9]. These inconsistent findings may be due to different cohort characteristics, a limited sample size of our study as compared to previous investigations, or other, yet unknown, reasons. Although vitamin D supplementation did not alter cardiovascular risk markers in our RCT analyses, we observed that the prevalence of diabetes mellitus and impaired glucose metabolism was significantly increased in individuals with versus without functional vitamin D deficiency.

This is an interesting finding that warrants further investigations that specifically address the relationship between functional vitamin D deficiency and diabetes mellitus and evaluate whether the risk of diabetes mellitus and disturbed glucose metabolism can be significantly reduced by vitamin D supplementation in individuals suffering from functional vitamin D deficiency. In addition to lower 1,25(OH)2D and other vitamin D metabolites, older age and a lower GFR were also more prevalent in individuals with functional vitamin D deficiency, and one might, therefore, speculate that the lower vitamin D catabolism associated with these parameters may hypothetically indicate a higher vitamin D requirement, unconsidered confounding factors or alterations in vitamin D metabolism related to these parameters.

Despite our findings of no significant benefits of vitamin D supplementation on bone metabolism and cardiovascular risk markers, we continue to urge other scientists to further evaluate whether the concept of “functional vitamin D deficiency” is useful for a better characterization and classification of vitamin D status. Many large vitamin D RCTs have been performed and recently published reporting, by the vast majority, no significant vitamin D effects, probably due to enrolling individuals with largely sufficient serum 25(OH)D concentrations. Measuring 24,25(OH)2D, if not yet available, in these RCTs and re-analyzing the existing data with analyses restricted to participants with functional vitamin D deficiency could be considered a great opportunity to further evaluate our hypothesis on whether individuals with functional vitamin D deficiency are particularly sensitive to beneficial vitamin D effects.

Importantly, some vitamin D RCTs with no significant effect in the overall, largely vitamin D-sufficient study population have shown benefits of vitamin D when restricting their analyses to individuals with very low 25(OH)D concentrations [18,19,20,21]. As our observational data suggest a particularly high risk of disturbed glucose metabolism in participants with functional vitamin D deficiency, we would particularly recommend evaluating the concept of functional vitamin D deficiency in vitamin D RCTs on diabetes-related outcomes [18,21,22].

While our findings do not support the hypothesis that individuals with functional vitamin D deficiency significantly benefit from vitamin D supplementation, we wish to underline that our LC-MS/MS method for simultaneous measurements of different vitamin D metabolites has some advantages over the widely used immuno-assay based determinations of serum 25(OH)D. First, despite significant efforts for quality control and standardization, a significant variability remains in the analytical performance of immuno-assays as opposed to LC/MS-MS methods [23,24]. Second, simultaneous measurements of 25(OH)D and 24,25(OH)2D by LC-MS/MS-based methods allow for the identification of individuals suffering from 24-hydroxylase deficiency caused by pathogenic mutations of CYP24A1 [25].

This inherited disease is characterized by hypercalcemia due to an impaired catabolism of vitamin D metabolites, with thus a low 24,25(OH)2D-to-25(OH)D ratio [25]. In addition, routine use of simultaneous measurement of 25(OH)D and 24,25(OH)2D by LC-MS/MS methods is also useful to distinguish between vitamin D intoxication and 24-hydroxylase deficiency due to pathogenic CYP24A1 mutations, as those with vitamin D intoxication have significantly higher 24,25(OH)2D concentrations when compared to those suffering from 24-hydroxylase deficiency [11]. We also want to stress that we are well aware that our assumption of functional vitamin D deficiency as a condition indicating high vitamin D requirements based on the consideration that the human body reduces vitamin D catabolism reflected by low 24,25(OH)D levels according to the prevailing vitamin D demand is just a simplified hypothesis.

Therefore, we stress that there exists a complex and partially unknown regulation of vitamin D metabolism, in particular of 24-hydroxylase activity, with many interacting factors [26,27,28]. Further research is warranted to better characterize vitamin D metabolism with the aim to further improve the identification of individuals who are most likely to benefit from vitamin D supplementation and to critically evaluate and eventually optimize the classification of functional vitamin D deficiency as applied in our study.

We have to acknowledge that our study is only a post hoc analysis of an RCT, and as only a small proportion of our trial participants suffered from functional vitamin D deficiency, we had a limited sample size. Nevertheless, applying a formal power calculation reveals that the expected sample sizes for our subgroup analyses in participants with functional vitamin D deficiency seem reasonable for most outcomes studied to detect clinically meaningful treatment effects (in the range of slightly less than one SD of the outcome measure) with a power of 80%.

External validity (generalizability) may also be limited as we investigated a cohort with arterial hypertension. Moreover, the study duration may have been too short to observe some effects that require long-term vitamin D supplementation. Other limitations are the relatively low number of participants with very low 25(OH)D levels (e.g., below 25/30 nmol/L) and missing data on vitamin D status before study inclusion. While our results argue against relatively large treatment effects of vitamin D supplementation in patients with functionally vitamin D deficiency, larger RCTs are required to evaluate whether there are smaller but still relevant treatment effects on a population level.

Regarding the classification of functional vitamin D deficiency, we adhered to a previously published empirical definition for this but are well aware that other approaches for this classification might be superior [9]. Our cross-sectional analyses and group comparisons are limited because they are only based on crude (unadjusted) analyses. We refrained from conducting multivariate-adjusted analyses regarding these cross-sectional data as the main aim of this work was to focus on the effect of vitamin D intervention rather than on association analyses.

In this context, we emphasize the need to test our hypothesis on functional vitamin D deficiency as a tool to identify individuals with high sensitivity to vitamin D supplementation in RCTs rather than performing multiple observational studies on this topic. Therefore, the main strengths of our work are that we tested our hypothesis in an RCT and followed an a priori-specified statistical analysis plan.

Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion

Results

Data on the VMR were available in 505 out of 518 persons who were screened for this study, of whom 192 suffered from vitamin D deficiency characterized by a serum 25(OH)D concentration below 50 nmol/L. In Table 1, we present the baseline characteristics of all persons screened for this study with available LC-/MS-MS-based measurements of vitamin D metabolites, stratified into those with 25(OH)D below 50 nmol/L and ≥50 nmol/L, respectively.

In Table 2, we present data for all participants screened for this study with 25(OH)D below 50 nmol/L, comparing baseline characteristics of groups with versus without functional vitamin D deficiency.

In Table 3, we present parameters of mineral metabolism at baseline and follow-up, as well as the treatment effect of vitamin D in study participants of the RCT with serum 25(OH)D below 50 nmol/L and functional vitamin D deficiency.

In Table 4, we present cardiovascular risk factors at baseline and follow-up, and the treatment effect of vitamin D in study participants of the RCT with serum 25(OH)D below 50 nmol/L and functional vitamin D deficiency.

Our results remained materially unchanged when males and females were analyzed separately.

Table 1

Baseline characteristics of all study participants, stratified according to serum 25-hydroxyvitamin D in those <50 nmol/L and ≥50 nmol/L.

CharacteristicsAll (n = 505)25(OH)D < 50 nmol/L (n = 195)25(OH)D ≥ 50 nmol/L (n = 310)p Value
Females (%)52.350.753.20.591
Age (years)61.2 ± 10.659.9 ± 11.362.0 ± 10.00.026
Body mass index (kg/m2)29.6 ± 5.130.8 ± 5.728.9 ± 4.6<0.001
Office systolic BP (mm Hg)141 ± 16.6141 ± 17.1141 ± 16.30.734
Office diastolic BP (mm Hg)86.3 ± 11.086.7 ± 11.786.1 ± 10.50.573
24 h systolic BP (mm Hg)128 ± 13.9 130 ± 14.3126 ± 13.40.002
24 h diastolic BP (mm Hg)76.4 ± 9.577.5 ± 10.375.8 ± 9.00.049
NT-proBNP (pg/mL)82 (42 to 153)83 (40.8 to 150)84 (45 to 158)0.428
Corrected QT interval (ms)413 (391 to 441)414 (391 to 445)413 (391 to 439)0.865
PRC (µU/mL)17.4 (10.1 to 48.3)18.6 (10.2 to 57.5)16.9 (9.6 to 44.3)0.596
PAC (ng/dL)17.0 ± 10.316.5 ± 10.217.3 ± 10.40.39
eGFR (mL/min/1.73 m2)79.2 ± 17.781.8 ± 18.778.1 ± 16.90.021
24 h UAE (mg/24 h)8.5 (6.0 to 19.8)9.0 (6.0 to 21.0)8.0 (6.0 to 17.0)0.064
Diabetes mellitus (%)26.534.921.3<0.001
Fasting glucose (mg/dL)112 ± 40.8121 ± 49.8107 ± 33.0<0.001
HbA1c (mmol/mol)43.6 ± 11.746.2 ± 14.241.9 ± 9.4<0.001
HOMA-IR1.73 (1.03 to 3.06)2.01 (1.24 to 3.93)1.56 (0.97 to 2.76)0.005
Triglycerides (mg/dL)110 (75.0 to 154)117 (73.8 to 164)105 (75.0 to 151)0.311
HDL cholesterol (mg/dL)58.6 ± 17.357.1 ± 17.459.5 ± 17.20.142
LDL cholesterol (mg/dL)114 ± 38.4113 ± 37.9115 ± 38.70.470
PWV (m/s)8.6 ± 2.48.5 ± 2.08.6 ± 2.60.861
CRP (mg/L)1.80 (0.80 to 3.40)1.70 (0.85 to 3.40)1.9 (0.80 to 3.50)0.933
25(OH)D (nmol/L)60.4 ± 26.736.1 ± 9.675.7 ± 22.4<0.001
24,25(OH)2D (nmol/L)3.7 ± 2.61.9 ± 1.15.1 ± 2.4<0.001
VMR (%)6.2 ± 2.35.2 ± 2.46.8 ± 2.0<0.001
1,25(OH)2D (pg/mL)52.5 ± 19.844.9 ± 17.457.2 ± 19.7<0.001
Fibroblast growth factor-23 (pmol/L)0.85 (0.60 to 1.25)0.88 (0.61 to 1.37)0.83 (0.59 to 1.21)0.072
bALP (µg/L)16.9 ± 6.217.3 ± 6.916.6 ± 5.70.380
CTX (ng/mL)0.22 ± 0.180.20 ± 0.150.24 ± 0.200.058
Osteocalcin (ng/mL)14.9 ± 8.414.4 ± 8.215.3 ± 8.50.216
P1NP (ng/mL)42.0 ± 21.040.7 ± 18.342.8 ± 22.50.283
PTH (pg/mL)51.1 ± 19.556.8 ± 22.047.4 ± 16.7<0.001
Plasma calcium (mmol/L)2.38 ± 0.112.37 ± 0.112.39 ± 0.100.017
24 h UCaE (mmol/24 h)3.72 ± 2.483.59 ± 2.623.80 ± 2.390.397
Calcium supplement (%)9.95.112.90.005
Vitamin D supplement (%)10.95.114.50.001

Data are presented as means with standard deviation, medians with interquartile range or as percentages. Comparisons between the vitamin D and placebo group were calculated with Student’s t test or with Chi-Square test. BP, blood pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PRC, plasma renin concentration; PAC, plasma aldosterone concentration; eGFR, estimated Glomerular Filtration Rate; UAE, Urinary Albumin Excretion; HOMA-IR, Homeostatis Model Assessment: Insulin Resistance; PWV, pulse wave velocity; CRP, C-Reactive Protein; 25(OH)D, 25-hydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; VMR, vitamin D metabolite ratio; 1,25(OH)2D, 1,25-dihydroxyvitamin D, bALP; bone-specific alkaline phosphatase; CTX, β-CrossLaps; P1NP, procollagen type 1 amino-terminal propeptide; PTH, parathyroid hormone; UCaE, urinary calcium excretion.

Table 2

Baseline characteristics of study participants with serum 25-hydroxyvitamin D < 50 nmol/L stratified in patients with and without functional vitamin D deficiency *.

Characteristics25(OH)D < 50 nmol/L (n = 66) with Functional Deficiency25(OH)D < 50 nmol/L (n = 126) without Functional Deficiencyp Value
Females (%)50.051.20.741
Age (years)62.3 ± 10.258.7 ± 11.70.035
Body mass index (kg/m2)31.0 ± 5.830.7 ± 5.60.722
Office systolic BP (mm Hg)144 ± 18.1140 ± 16.60.187
Office diastolic BP (mm Hg)86.4 ± 11.686.9 ± 11.80.780
24 h systolic BP (mm Hg)131 ± 15.8130 ± 13.50.550
24 h diastolic BP (mm Hg)76.7 ± 9.677.9 ± 10.60.470
NT-proBNP (pg/mL)82.5 (39.0 to 171)87.5 (37.3 to 165)0.717
Corrected QT interval (ms)407 (388 to 437)416 (392 to 442)0.150
PRC (µU/mL)19.0 (12.4 to 79.3)17.4 (8.5 to 51.8)0.127
PAC (ng/dL)18.5 ± 9.415.5 ± 10.60.055
eGFR (mL/min/1.73 m2)76.5 ± 21.184.6 ± 16.80.004
24 h UAE (mg/24 h)9.0 (6.0 to 24.5)9.0 (6.0 to 21.0)0.604
Diabetes mellitus (%)54.445.6<0.001
Fasting glucose (mg/dL)141 ± 61.2110 ± 39.0<0.001
HbA1c (mmol/mol)52.6 ± 17.542.8 ± 10.8<0.001
HOMA-IR2.6 (1.5 to 5.7)2.1 (1.3 to 3.5)0.061
Triglycerides (mg/dL)117 (70.5 to 178)118 (81.8 to 150)0.504
HDL cholesterol (mg/dL)55.8 ± 20.357.8 ± 15.70.437
LDL cholesterol (mg/dL)107 ± 38.7116 ± 37.20.115
PWV (m/s)8.8 ± 2.08.4 ± 2.10.240
CRP (mg/L)1.95 (1.10 to 4.75)1.90 (0.90 to 3.40)0.017
25(OH)D (nmol/L)31.5 ± 9.738.4 ± 8.8<0.001
24,25(OH)2D (nmol/L)0.85 ± 0.462.38 ± 0.96<0.001
VMR (%)2.76 ± 0.936.43 ± 1.85<0.001
1,25(OH)2D (pg/mL)39.4 ± 18.047.7 ± 16.40.001
Fibroblast growth factor-23 (pmol/L)1.00 (0.69 to 1.44)0.89 (0.57 to 1.37)0.383
bALP (µg/L)18.1 ± 7.217.0 ± 6.70.556
CTX (ng/mL)0.19 ± 0.140.21 ± 0.150.454
Osteocalcin (ng/mL)14.0 ± 9.414.5 ± 7.50.681
P1NP (ng/mL)37.4 ± 14.442.3 ± 19.80.083
PTH (pg/mL)57.1 ± 26.756.7 ± 19.30.917
Plasma calcium (mmol/L)2.37 ± 0.112.37 ± 0.110.958
24 h UCaE (mmol/24 h)3.44 ± 2.793.67 ± 2.530.592
Calcium supplement (%)2.06.30.499
Vitamin D supplement (%)4.55.60.900

* Functional vitamin D deficiency is classified in persons with 24,25(OH)2D below 3 nmol/L and a VMR of less than 4%. Data are presented as means with standard deviation, medians with interquartile range or as percentages. Comparisons between the vitamin D and placebo group were calculated with Student’s t test or with Chi-Square test. BP, blood pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PRC, plasma renin concentration; PAC, plasma aldosterone concentration; eGFR, estimated Glomerular Filtration Rate; UAE, Urinary Albumin Excretion; HOMA-IR, Homeostatis Model Assessment: Insulin Resistance; PWV, pulse wave velocity; CRP, C-Reactive Protein; 25(OH)D, 25-hydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; VMR, vitamin D metabolite ratio; 1,25(OH)2D, 1,25-dihydroxyvitamin D; bALP, bone-specific alkaline phosphatase; CTX, β-CrossLaps; P1NP, procollagen type 1 amino-terminal propeptide; PTH, parathyroid hormone; UCaE, urinary calcium excretion.

Table 3

Parameters of mineral metabolism at baseline and follow-up, as well as changes from baseline in study participants with functional vitamin D deficiency and available values at both study visits.

CharacteristicsBaselineFollow-UpTreatment Effectp Value
25-hydroxyvitamin D (nmol/L)
     Vitamin D (n = 27)38.9 ± 14.368.8 ± 11.230.9 (24.4 to 37.5)<0.001
      Placebo (n = 22)38.9 ± 12.937.1 ± 14.0
24,25(OH)2D (nmol/L)
     Vitamin D (n = 25)1.16 ± 0.624.54 ± 1.142.6 (2.0 to 3.3)<0.001
     Placebo (n = 22)1.15 ± 0.571.88 ± 1.11
Vitamin D metabolite ratio (%)
     Vitamin D (n = 25)3.00 ± 0.956.79 ± 1.671.9 (1.1 to 2.6)<0.001
     Placebo (n = 22)3.00 ± 0.675.04 ± 1.59
1,25-dihydroxyvitamin D (pg/mL)
     Vitamin D (n = 19)50.5 ± 20.961.8 ± 27.66.2 (−7.8 to 20.1)0.377
     Placebo (n = 18)38.3 ± 17.743.3 ± 17.2
Fibroblast growth factor-23 (pmol/L)
     Vitamin D (n = 18)0.83 ± 0.712.01 ± 4.351.5 (−0.56 to 3.61)0.147
     Placebo (n = 17)1.34 ± 1.301.14 ± 0.49
Bone-specific alkaline phosphatase (µg/L)
     Vitamin D (n = 17)16.5 ± 7.616.6 ± 5.70.67 (−2.95 to 1.61)0.553
     Placebo (n = 16)19.8 ± 6.419.2 ± 6.5
β-CrossLaps (ng/mL)
     Vitamin D (n = 14)0.19 ± 0.120.18 ± 0.11−0.011 (−0.078 to 0.057)0.747
     Placebo (n = 16)0.19 ± 0.140.23 ± 0.16
Osteocalcin (ng/mL)
     Vitamin D (n = 18)12.6 ± 6.913.2 ± 5.90.46 (−2.060 to 2.986)0.711
     Placebo (n = 17)13.4 ± 6.714.4 ± 5.3
Procollagen typ 1 amino-terminal propetide (ng/mL)
     Vitamin D (n = 18)35.6 ± 17.538.5 ± 16.6−1.435 (−6.52 to 9.39)0.715
     Placebo (n = 17)40.2 ± 13.941.1 ± 11.7
Parathyroid hormone (pg/mL)#
     Vitamin D (n = 19)52.2 ± 23.446.9 ± 15.7−12.2 (−22.1 to −2.3)0.017
     Placebo (n = 20)50.9 ± 21.655.4 ± 29.6
Plasma calcium (mmol/L)
     Vitamin D (n = 19)2.38 ± 0.082.36 ± 0.07−0.008 (−0.055 to 0.040)0.747
     Placebo (n = 20)2.38 ± 0.142.37 ± 0.13
24 h urinary calcium excretion (mmol/24 h) #
     Vitamin D (n = 12)3.30 (2.10 to 7.20)3.74 (2.05 to 6.86)−0.19 (−1.34 to 1.72)0.802
     Placebo (n = 15)2.05 (1.28 to 5.40)2.53 (0.65 to 6.24)

Data at baseline and follow-up are shown as means with standard deviation or as medians with interquartile range. Treatment effects (with 95% confidence intervals) and p values were calculated by analysis of co-variance (ANCOVA) for group differences at follow-up with adjustment for baseline values; # skewed variable for which logarithmically transformed values were used in ANCOVA, but untransformed values are shown in the table.

Table 4

Cardiovascular outcome variables at baseline and follow-up and changes from baseline in study participants with functional vitamin D deficiency and available values at both study visits.

CharacteristicsBaselineFollow-UpTreatment Effectp Value
24 h systolic blood pressure (mm Hg)
     Vitamin D (n = 24)131 ± 9.5129 ± 9.3−1.14 (−6.10 to 3.83)0.647
     Placebo (n = 24)134 ± 7.4132 ± 10.6
24 h diastolic blood pressure (mm Hg)
     Vitamin D (n = 24)78.7 ± 7.676.7 ± 8.7−0.64 (−3.64 to 2.36)0.668
     Placebo (n = 24)77.8 ± 7.3 76.4 ± 8.7
N-terminal pro-B-type natriuretic peptide (ng/L) #
     Vitamin D (n = 26)45.0 (29.5 to 76.3)58.5 (35.8 to 134)2.55 (−69.5 to 74.6)0.944
     Placebo (n = 25)99.0 (45.5 to 228)98.0 (50.5 to 188)
Corrected QT interval (ms)
     Vitamin D (n = 23)409 ± 30.8422 ± 30.819.4 (−32.4 to 71.2)0.455
     Placebo (n = 24)417 ± 33.9423 ± 29.9
Plasma renin concentration (µU/mL) #
     Vitamin D (n = 24)18.3 (11.4 to 70.7)15.0 (10.6 to 47.0)−7.78 (−23.5 to 7.99)0.326
     Placebo (n = 23)14.9 (9.0 to 37.2)17.1 (8.8 to 46.7)
Plasma aldosterone concentration (ng/dL)
     Vitamin D (n = 26)16.8 ± 7.117.4 ± 6.62.53 (−1.55 to 6.62)0.218
     Placebo (n = 25)19.9 ± 10.922.8 ± 14.3
24 h urinary albumin concentration (mg/24 h) #
     Vitamin D (n = 12)7.0 (6.0 to 13.0)8.0 (7.9 to 11.9)6.99 (−14.7 to 28.7)0.509
     Placebo (n = 14)8.0 (4.0 to 120)8.0 (4.8 to 23.4)
Homeostasis Model Assessment: Insulin Resistance #
     Vitamin D (n = 26)2.38 (1.11 to 5.48)2.53 (1.38 to 4.75)0.41 (−3.1 to 3.9)0.812
     Placebo (n = 23)3.08 (1.40 to 6.80)3.79 (1.60 to 7.28)
Triglycerides (mg/dL)
     Vitamin D (n = 26)132 ± 78.0135 ± 80.82.63 (−25.2 to 30.5)0.850
     Placebo (n = 25)136 ± 72.4140 ± 64.7
HDL cholesterol (mg/dL)
     Vitamin D (n = 26)54.7 ± 15.754.9 ± 17.40.42 (−3.90 to 4.75)0.845
     Placebo (n = 25)53.2 ± 15.853.8 ± 17.2
Pulse wave velocity (m/s)
     Vitamin D (n = 23)8.68 ± 1.768.93 ± 2.320.59 (−0.57 to 1.76)0.308
     Placebo (n = 15)9.08 ± 2.588.41 ± 2.46

Data at baseline and follow-up are shown as means with standard deviation or as medians with interquartile range. Treatment effects (with 95% confidence intervals) and p values were calculated by analaysis of co-variance (ANCOVA) for group differences at follow-up with adjustment for baseline values; # skewed variable for which logarithmically transformed values were used in ANCOVA but untransformed values are shown in the table.

Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results

Conclusions

In conclusion, our criteria for functional vitamin D deficiency did not show that vitamin D-deficient patients significantly benefit from vitamin D supplementation regarding bone markers and cardiovascular risk factors, except for a decrease in PTH and expected changes in vitamin D metabolites. Further studies, in particular large RCTs, are warranted to explore whether the measurements of vitamin D metabolites in addition to 25(OH)D are useful for the classification of vitamin D status and identification of individuals who particularly benefit from vitamin D treatment.

Source: 5. Conclusions
Authors’ abstract

Circulating 25-hydroxyvitamin D (25(OH)D) is the generally accepted indicator of vitamin D status. Since hydroxylation of 25(OH)D to 24-25-dihydroxyvitamin D (24,25(OH)2D) is the first step of its catabolism, it has been suggested that a low 24,25(OH)D level and a low vitamin D metabolite ratio (VMR), i.e., 24,25(OH)2D divided by 25(OH)D, may indicate high vitamin D requirements and provide additional diagnostic information beyond serum 25(OH)D. We, therefore, evaluated whether the classification of “functional vitamin D deficiency”, i.e., 25(OH)D below 50 nmol/L, 24,25(OH)2D below 3 nmol/L and a VMR of less than 4%, identifies individuals who benefit from vitamin D supplementation.

In participants of the Styrian Vitamin D Hypertension trial, a randomized controlled trial (RCT) in 200 hypertensive patients with serum 25(OH)D below 75 nmol/L, who received either 2.800 international units of vitamin D per day or placebo over 8 weeks, 51 participants had functional vitamin D deficiency. In these individuals, there was no treatment effect of vitamin D supplementation on various parameters of bone metabolism and cardiovascular risk except for a significant effect on parathyroid hormone (PTH) and expected changes in vitamin D metabolites.

In conclusion, a low vitamin D metabolite profile did not identify individuals who significantly benefit from vitamin D supplementation with regard to bone markers and cardiovascular risk factors. The clinical significance of functional vitamin D deficiency requires further evaluation in large vitamin D RCTs.

Read the full paper

1. Introduction

There exists a wide consensus that the assessment of vitamin D status is performed by measuring serum 25-hydroxyvitamin D (25(OH)D) concentrations [1,2]. An ongoing scientific controversy prevails regarding the precise 25(OH)D cut-offs for defining vitamin D deficiency and sufficiency [1,3,4]. Due to unknown reasons, vitamin D requirements seem to be met at extremely low serum 25(OH)D concentrations for some individuals, whereas others require higher serum 25(OH)D levels to satisfy their vitamin D needs [3,5,6,7,8].

Measuring 24,25-dihydroxyvitamin D (24,25(OH)2D) in addition to 25(OH)D and calculating the vitamin D metabolite ratio (VMR) out of these two molecules (i.e., 24,25(OH)2D divided by 25(OH)D) may serve as an indicator of “functional vitamin D deficiency” that may overcome some of the limitations of exclusively measuring serum 25(OH)D for vitamin D status assessment [9]. The basic concept behind this approach is that the hydroxylation of 25(OH)D to 24,25(OH)2D is considered the first step in the catabolism of vitamin D.

Assuming that the human body regulates, at least in part, vitamin D metabolism according to the individual demands, a lower catabolism, and thus lower relative concentration of 24,25(OH)2D and a subsequently lower VMR, may hypothetically indicate a higher vitamin D requirement and vice versa [9] (see Figure 1).

There is still no established consensus regarding a universal definition of functional vitamin D deficiency, but based on previous reports, we classify functional vitamin D deficiency in individuals with 25(OH)D below 50 nmol/L (multiplied by 2.496 to convert ng/mL to nmol/L), 24,25(OH)2D below 3 nmol/L and a VMR of less than 4% [9].

Controversial data exist on whether VMR predicts increases in 25(OH)D after vitamin D supplementation, with a previous investigation of our group failing to document such an effect [10]. By contrast, some studies have already suggested that assessment of vitamin D status by using the VMR for defining functional vitamin D deficiency may provide useful information in addition to serum 25(OH)D alone [9,11,12,13,14,15]. In this context, better characterization of bone health and mortality risk has been reported for this approach as opposed to conventional vitamin D status assessment [9,13,15].

Data on this issue are, however, limited to only a few studies, and there exists a knowledge gap regarding randomized controlled trials (RCTs) evaluating clinically relevant vitamin D effects in persons with functional vitamin D deficiency.

In this work, we aim to evaluate the hypothesis that the definition of functional vitamin D deficiency is able to identify individuals who significantly benefit from vitamin D supplementation. This study is a post hoc analysis of the Styrian Vitamin D Hypertension Study, an RCT in 200 hypertensive patients with low 25(OH)D, on vitamin D supplementation with 2.800 international units (IU) (50 µg) daily for 8 weeks [16]. In individuals with serum 25(OH)D concentrations below 50 nmol/L, we evaluate, as our primary outcome analyses, whether those with functional vitamin D deficiency significantly benefit from vitamin D supplementation concerning markers of bone metabolism and cardiovascular risk.

In addition, we evaluate in cross-sectional analyses whether individuals with and without functional vitamin D deficiency differ with regard to various clinical and laboratory characteristics.

2. Materials and Methods

2.1. Study Design

The Styrian Vitamin D Hypertension Study is a double-blind, placebo-controlled trial in 200 hypertensive patients with serum 25(OH)D below 75 nmol/L from the Department of Internal Medicine of the Medical University of Graz. In total, 518 study participants were screened for this study (of whom 200 were included in the RCT) and are thus part of the entire study cohort termed Styrian Hypertension Study. The main objective of the initial trial was to evaluate whether vitamin D supplementation with 2.800 international units (IU) daily for 8 weeks reduces 24 h systolic ambulatory blood pressure (ABP) compared to placebo.

Secondary endpoints included 24 h diastolic ABP and other cardiovascular risk factors. All study participants gave written informed consent, and the ethics committee at the Medical University of Graz, Austria, approved the initial study and the additional analyses of this present post hoc analysis. The study was registered at EU Clinical Trials Register (http://www.clinicaltrialsregister.eu (accessed on 23 February 2024), EudraCT number 2009-018125-70) and at clinicaltrials.gov (ClinicalTrials.gov Identifier NCT02136771). The publications of this RCT adhere to the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement.

Further details on the study methods and the main study findings of this RCT were published elsewhere [16]. For the current investigation, we included only individuals with available data to calculate the VMR, i.e., data on 25(OH)D and 24,25(OH)2D.

2.2. Laboratory Measurements

In serum samples that were stored at −80° Celsius from blood collection until analysis in October 2023, 25(OH)D and 24,25(OH)2D were determined by a validated LC-MS/MS method that is regularly evaluated by internal and external quality controls with satisfactory results [17]. For external quality assessment, this method is enrolled in the Vitamin D External Quality Assessment Scheme (DEQAS) that uses target values assigned by the Centers for Disease Control and Prevention (CDC) reference measurement procedure (i.e., certified reference material (SRM 2972a) from the National Institute of Standards and Technology (NIST)).

For all vitamin D metabolites, the intra: and inter-day imprecision was <9% and <12%, respectively, and the limit of detection (LOD) and limit of quantification (LOQ) ranged from 0.12 to 0.60 ng/mL (0.3 to 1.5 nmol/L) and 0.40 to 1.24 ng/mL (1.0 to 3.1 nmol/L), respectively. Recovery varied between 76.1% and 84.3%. Regarding bone markers, β-CrossLaps (CTX), osteocalcin and procollagen type 1 amino-terminal propetide (P1NP) were determined by electrochemiluminescence immunoassays (Roche Diagnostics, Mannheim, Germany) according to manufacturers’ instructions. Bone-specific alkaline phosphatase (bALP) was measured by a spectrophotometric immunoassay (Immunodiagnostic Systems Ltd., Boldon, UK). 1,25-dihydroxyvitamin D (1,25(OH)2D) concentrations were determined by a chemoluminescence immunoassay (Immunodiagnostic Systems Ltd., Boldon, UK) and C-terminal fibroblast growth factor-23 (FGF-23) by a multi matrix ELISA (BIOMEDICA Medizinprodukte GmbH & CO KG, Vienna, Austria).

In addition to vitamin D metabolites and bone markers, several other laboratory parameters were determined by methods that have been described elsewhere [16].

2.3. Outcome Measures

All primary and secondary outcome measures of the initial RCT were re-analyzed as part of this investigation. In addition, for analyses on bone and mineral metabolism, we also included 24,25(OH)2D, VMR, 1,25(OH)2D, FGF-23, bALP, CTX, osteocalcin and P1NP.

2.4. Statistical Analyses

Continuous data with a normal distribution are shown as means with standard deviation (SD), and non-normally distributed variables are shown as medians with 25th to 75th percentile. Categorical variables are presented as percentages. Non-normally distributed variables are log(e)-transformed before use in parametric procedures. Group comparisons of individuals with and without functional vitamin D deficiency are performed by Chi-Square test and Student’s t test. In individuals with functional vitamin D deficiency, analysis of co-variance (ANCOVA) with adjustment for baseline values is used to test for differences between the vitamin D and the placebo group.

No data imputation was performed for missing values. All analyses are exploratory for these post hoc analyses. A power calculation revealed that the expected sample sizes for our subgroup analyses in participants with functional vitamin D deficiency seem reasonable for most outcomes studied. For example, for the primary outcome measure of the initial RCT publication, i.e., 24 h systolic ABP, we calculated, with a power of 80% and an α of 0.05, a sample size of 22 participants per study group (44 participants overall) when assuming an effect size of 8 mm Hg and an SD of 9 mm Hg.

A p-value below 0.05 was considered statistically significant. Statistical analyses were performed by using SPSS Version 27 (SPS, Chicago, IL, USA).

3. Results

Data on the VMR were available in 505 out of 518 persons who were screened for this study, of whom 192 suffered from vitamin D deficiency characterized by a serum 25(OH)D concentration below 50 nmol/L. In Table 1, we present the baseline characteristics of all persons screened for this study with available LC-/MS-MS-based measurements of vitamin D metabolites, stratified into those with 25(OH)D below 50 nmol/L and ≥50 nmol/L, respectively.

In Table 2, we present data for all participants screened for this study with 25(OH)D below 50 nmol/L, comparing baseline characteristics of groups with versus without functional vitamin D deficiency.

In Table 3, we present parameters of mineral metabolism at baseline and follow-up, as well as the treatment effect of vitamin D in study participants of the RCT with serum 25(OH)D below 50 nmol/L and functional vitamin D deficiency.

In Table 4, we present cardiovascular risk factors at baseline and follow-up, and the treatment effect of vitamin D in study participants of the RCT with serum 25(OH)D below 50 nmol/L and functional vitamin D deficiency.

Our results remained materially unchanged when males and females were analyzed separately.

4. Discussion

In vitamin D-deficient hypertensive patients, those with functional vitamin D deficiency did not yield significant benefits in response to vitamin D supplementation with regard to markers of bone health and cardiovascular risk except for a decrease in PTH concentrations and expected changes in vitamin D metabolites. Cross-sectional analyses in vitamin D-deficient individuals showed, amongst others, a significantly higher prevalence of diabetes mellitus and disturbed glucose metabolism in those with versus without functional vitamin D deficiency.

Our study is, to the best of our knowledge, the first to evaluate whether individuals with “functional vitamin D deficiency” significantly benefit from vitamin D supplementation regarding markers of bone health and cardiovascular risk. As in our initial publication of this RCT, we did not detect significant benefits of vitamin D supplementation apart from well-established effects on PTH and expected changes in vitamin D metabolites. Our work was stimulated by previous observational data suggesting that individuals with functional vitamin D deficiency, i.e., those with relatively low 24,25(OH)2D concentrations and a low VMR, had adverse bone health and higher mortality risk as compared to individuals with an unremarkable vitamin D profile [9,13,15].

In this context, we could not confirm the findings derived from other cohorts that individuals with functional vitamin D deficiency had an adverse profile regarding bone turnover markers [9]. These inconsistent findings may be due to different cohort characteristics, a limited sample size of our study as compared to previous investigations, or other, yet unknown, reasons. Although vitamin D supplementation did not alter cardiovascular risk markers in our RCT analyses, we observed that the prevalence of diabetes mellitus and impaired glucose metabolism was significantly increased in individuals with versus without functional vitamin D deficiency.

This is an interesting finding that warrants further investigations that specifically address the relationship between functional vitamin D deficiency and diabetes mellitus and evaluate whether the risk of diabetes mellitus and disturbed glucose metabolism can be significantly reduced by vitamin D supplementation in individuals suffering from functional vitamin D deficiency. In addition to lower 1,25(OH)2D and other vitamin D metabolites, older age and a lower GFR were also more prevalent in individuals with functional vitamin D deficiency, and one might, therefore, speculate that the lower vitamin D catabolism associated with these parameters may hypothetically indicate a higher vitamin D requirement, unconsidered confounding factors or alterations in vitamin D metabolism related to these parameters.

Despite our findings of no significant benefits of vitamin D supplementation on bone metabolism and cardiovascular risk markers, we continue to urge other scientists to further evaluate whether the concept of “functional vitamin D deficiency” is useful for a better characterization and classification of vitamin D status. Many large vitamin D RCTs have been performed and recently published reporting, by the vast majority, no significant vitamin D effects, probably due to enrolling individuals with largely sufficient serum 25(OH)D concentrations. Measuring 24,25(OH)2D, if not yet available, in these RCTs and re-analyzing the existing data with analyses restricted to participants with functional vitamin D deficiency could be considered a great opportunity to further evaluate our hypothesis on whether individuals with functional vitamin D deficiency are particularly sensitive to beneficial vitamin D effects.

Importantly, some vitamin D RCTs with no significant effect in the overall, largely vitamin D-sufficient study population have shown benefits of vitamin D when restricting their analyses to individuals with very low 25(OH)D concentrations [18,19,20,21]. As our observational data suggest a particularly high risk of disturbed glucose metabolism in participants with functional vitamin D deficiency, we would particularly recommend evaluating the concept of functional vitamin D deficiency in vitamin D RCTs on diabetes-related outcomes [18,21,22].

While our findings do not support the hypothesis that individuals with functional vitamin D deficiency significantly benefit from vitamin D supplementation, we wish to underline that our LC-MS/MS method for simultaneous measurements of different vitamin D metabolites has some advantages over the widely used immuno-assay based determinations of serum 25(OH)D. First, despite significant efforts for quality control and standardization, a significant variability remains in the analytical performance of immuno-assays as opposed to LC/MS-MS methods [23,24]. Second, simultaneous measurements of 25(OH)D and 24,25(OH)2D by LC-MS/MS-based methods allow for the identification of individuals suffering from 24-hydroxylase deficiency caused by pathogenic mutations of CYP24A1 [25].

This inherited disease is characterized by hypercalcemia due to an impaired catabolism of vitamin D metabolites, with thus a low 24,25(OH)2D-to-25(OH)D ratio [25]. In addition, routine use of simultaneous measurement of 25(OH)D and 24,25(OH)2D by LC-MS/MS methods is also useful to distinguish between vitamin D intoxication and 24-hydroxylase deficiency due to pathogenic CYP24A1 mutations, as those with vitamin D intoxication have significantly higher 24,25(OH)2D concentrations when compared to those suffering from 24-hydroxylase deficiency [11]. We also want to stress that we are well aware that our assumption of functional vitamin D deficiency as a condition indicating high vitamin D requirements based on the consideration that the human body reduces vitamin D catabolism reflected by low 24,25(OH)D levels according to the prevailing vitamin D demand is just a simplified hypothesis.

Therefore, we stress that there exists a complex and partially unknown regulation of vitamin D metabolism, in particular of 24-hydroxylase activity, with many interacting factors [26,27,28]. Further research is warranted to better characterize vitamin D metabolism with the aim to further improve the identification of individuals who are most likely to benefit from vitamin D supplementation and to critically evaluate and eventually optimize the classification of functional vitamin D deficiency as applied in our study.

We have to acknowledge that our study is only a post hoc analysis of an RCT, and as only a small proportion of our trial participants suffered from functional vitamin D deficiency, we had a limited sample size. Nevertheless, applying a formal power calculation reveals that the expected sample sizes for our subgroup analyses in participants with functional vitamin D deficiency seem reasonable for most outcomes studied to detect clinically meaningful treatment effects (in the range of slightly less than one SD of the outcome measure) with a power of 80%.

External validity (generalizability) may also be limited as we investigated a cohort with arterial hypertension. Moreover, the study duration may have been too short to observe some effects that require long-term vitamin D supplementation. Other limitations are the relatively low number of participants with very low 25(OH)D levels (e.g., below 25/30 nmol/L) and missing data on vitamin D status before study inclusion. While our results argue against relatively large treatment effects of vitamin D supplementation in patients with functionally vitamin D deficiency, larger RCTs are required to evaluate whether there are smaller but still relevant treatment effects on a population level.

Regarding the classification of functional vitamin D deficiency, we adhered to a previously published empirical definition for this but are well aware that other approaches for this classification might be superior [9]. Our cross-sectional analyses and group comparisons are limited because they are only based on crude (unadjusted) analyses. We refrained from conducting multivariate-adjusted analyses regarding these cross-sectional data as the main aim of this work was to focus on the effect of vitamin D intervention rather than on association analyses.

In this context, we emphasize the need to test our hypothesis on functional vitamin D deficiency as a tool to identify individuals with high sensitivity to vitamin D supplementation in RCTs rather than performing multiple observational studies on this topic. Therefore, the main strengths of our work are that we tested our hypothesis in an RCT and followed an a priori-specified statistical analysis plan.

5. Conclusions

In conclusion, our criteria for functional vitamin D deficiency did not show that vitamin D-deficient patients significantly benefit from vitamin D supplementation regarding bone markers and cardiovascular risk factors, except for a decrease in PTH and expected changes in vitamin D metabolites. Further studies, in particular large RCTs, are warranted to explore whether the measurements of vitamin D metabolites in addition to 25(OH)D are useful for the classification of vitamin D status and identification of individuals who particularly benefit from vitamin D treatment.

Acknowledgments

We thank all study participants.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Author Contributions

Conceptualization, S.Z., A.M. and S.P.; Data Curation S.Z., A.M., M.H.K., A.T. and S.P.; Formal Analysis, S.Z. and A.M.; Funding Acquisition, S.P.; Investigation, M.H.K., A.T. and S.P.; Methodology, S.P.; Project Administration, S.P.; Writing: Original Draft, S.P.; Writing: Review and Editing, S.Z., A.M., D.E., M.H.K., M.H., V.T.-S., C.T., L.S., A.T., P.S., J.D., P.P., A.Z., W.M., S.P. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical University of Graz, Austria (EK-Nr.: 21-155 ex 09/10; date of ethical approval: 29 June 2011).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to data protection regulation issues.

Conflicts of Interest

Winfried März was employed by the company SYNLAB Academy, Synlab Holding Deutschland GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Bouillon R. Comparative analysis of nutritional guidelines for vitamin D Nat. Rev. Endocrinol. 2017 13 466 479 10.1038/nrendo.2017.31 28387318
2. Buttriss J.L. Lanham-New S.A. Steenson S. Levy L. Swan G.E. Darling A.L. Cashman K.D. Allen R.E. Durrant L.R. Smith C.P. Implementation strategies for improving vitamin D status and increasing vitamin D intake in the UK: Current controversies and future perspectives: Proceedings of the 2nd Rank Prize Funds Forum on vitamin D Br. J. Nutr. 2022 127 1567 1587 10.1017/S0007114521002555 34284830 PMC8376911
3. Pludowski P. Takacs I. Boyanov M. Belaya Z. Diaconu C.C. Mokhort T. Zherdova N. Rasa I. Payer J. Pilz S. Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement Nutrients 2022 14 1483 10.3390/nu14071483 35406098 PMC9002638
4. Holick M.F. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention Rev. Endocr. Metab. Disord. 2017 18 153 165 10.1007/s11154-017-9424-1 28516265
5. Ross A.C. Manson J.E. Abrams S.A. Aloia J.F. Brannon P.M. Clinton S.K. Durazo-Arvizu R.A. Gallagher J.C. Gallo R.L. Jones G. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know J. Clin. Endocrinol. Metab. 2011 96 53 58 10.1210/jc.2010-2704 21118827 PMC3046611
6. Priemel M. von Domarus C. Klatte T.O. Kessler S. Schlie J. Meier S. Proksch N. Pastor F. Netter C. Streichert T. Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients J. Bone Min. Res. 2010 25 305 312 10.1359/jbmr.090728 19594303
7. Thiering E. Bruske I. Kratzsch J. Hofbauer L.C. Berdel D. von Berg A. Lehmann I. Hoffmann B. Bauer C.P. Koletzko S. Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children Sci. Rep. 2015 5 18138 10.1038/srep18138 26667774 PMC4678865
8. Zhao J. Cai Q. Jiang D. Wang L. Chen S. Jia W. The Associations of Serum Vitamin D and Bone Turnover Markers with the Type and Severity of Hip Fractures in Older Women Clin. Interv. Aging 2020 15 1971 1978 10.2147/CIA.S271904 33116451 PMC7574903
9. Herrmann M. Zelzer S. Cavalier E. Kleber M. Drexler-Helmberg C. Schlenke P. Curcic P. Keppel M.H. Enko D. Scharnagl H. Functional Assessment of Vitamin D Status by a Novel Metabolic Approach: The Low Vitamin D Profile Concept Clin. Chem. 2023 69 1307 1316 10.1093/clinchem/hvad151 37798100
10. Francic V. Ursem S.R. Dirks N.F. Keppel M.H. Theiler-Schwetz V. Trummer C. Pandis M. Borzan V. Grubler M.R. Verheyen N.D. The Effect of Vitamin D Supplementation on its Metabolism and the Vitamin D Metabolite Ratio Nutrients 2019 11 2539 10.3390/nu11102539 31640241 PMC6836132
11. Cavalier E. Huyghebaert L. Rousselle O. Bekaert A.C. Kovacs S. Vranken L. Peeters S. Le Goff C. Ladang A. Simultaneous measurement of 25(OH)-vitamin D and 24,25(OH)2-vitamin D to define cut-offs for CYP24A1 mutation and vitamin D deficiency in a population of 1200 young subjects Clin. Chem. Lab. Med. 2020 58 197 201 10.1515/cclm-2019-0996 31804956
12. Wagner D. Hanwell H.E. Schnabl K. Yazdanpanah M. Kimball S. Fu L. Sidhom G. Rousseau D. Cole D.E. Vieth R. The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation J. Steroid Biochem. Mol. Biol. 2011 126 72 77 10.1016/j.jsbmb.2011.05.003 21605672
13. Ginsberg C. Katz R. de Boer I.H. Kestenbaum B.R. Chonchol M. Shlipak M.G. Sarnak M.J. Hoofnagle A.N. Rifkin D.E. Garimella P.S. The 24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: The cardiovascular health study Bone 2018 107 124 130 10.1016/j.bone.2017.11.011 29155243 PMC5794222
14. Ginsberg C. Hoofnagle A.N. Katz R. Becker J.O. Kritchevsky S.B. Shlipak M.G. Sarnak M.J. Ix J.H. The Vitamin D Metabolite Ratio Is Independent of Vitamin D Binding Protein Concentration Clin. Chem. 2021 67 385 393 10.1093/clinchem/hvaa238 33188595 PMC8880257
15. Ginsberg C. Hoofnagle A.N. Katz R. Hughes-Austin J. Miller L.M. Becker J.O. Kritchevsky S.B. Shlipak M.G. Sarnak M.J. Ix J.H. The Vitamin D Metabolite Ratio Is Associated wsith Changes in Bone Density and Fracture Risk in Older Adults J. Bone Min. Res. 2021 36 2343 2350 10.1002/jbmr.4426 PMC8688212 34423858
16. Pilz S. Gaksch M. Kienreich K. Grubler M. Verheyen N. Fahrleitner-Pammer A. Treiber G. Drechsler C. Hartaigh B.ó. Obermayer-Pietsch B. Effects of vitamin D on blood pressure and cardiovascular risk factors: A randomized controlled trial Hypertension 2015 65 1195 1201 10.1161/HYPERTENSIONAHA.115.05319 25801871
17. Zelzer S. Meinitzer A. Enko D. Simstich S. Le Goff C. Cavalier E. Herrmann M. Goessler W. Simultaneous determination of 24,25: and 25,26-dihydroxyvitamin D3 in serum samples with liquid-chromatography mass spectrometry: A useful tool for the assessment of vitamin D metabolism J. Chromatogr. B 2020 1158 122394 10.1016/j.jchromb.2020.122394 33091679
18. Pittas A.G. Jorde R. Kawahara T. Dawson-Hughes B. Vitamin D Supplementation for Prevention of Type 2 Diabetes Mellitus: To D or Not to D? J. Clin. Endocrinol. Metab. 2020 105 3721 3733 10.1210/clinem/dgaa594 32844212 PMC7571449
19. Scragg R. Sluyter J.D. Is There Proof of Extraskeletal Benefits From Vitamin D Supplementation From Recent Mega Trials of Vitamin D? JBMR Plus 2021 5 e10459 10.1002/jbm4.10459 33553994 PMC7839821
20. Jolliffe D.A. Camargo C.A. Jr. Sluyter J.D. Aglipay M. Aloia J.F. Ganmaa D. Bergman P. Bischoff-Ferrari H.A. Borzutzky A. Damsgaard C.T. Vitamin D supplementation to prevent acute respiratory infections: A systematic review and meta-analysis of aggregate data from randomised controlled trials Lancet Diabetes Endocrinol. 2021 9 276 292 10.1016/S2213-8587(21)00051-6 33798465
21. Pittas A.G. Dawson-Hughes B. Sheehan P. Ware J.H. Knowler W.C. Aroda V.R. Brodsky I. Ceglia L. Chadha C. Chatterjee R. Vitamin D Supplementation and Prevention of Type 2 Diabetes N. Engl. J. Med. 2019 381 520 530 10.1056/NEJMoa1900906 31173679 PMC6993875
22. Dawson-Hughes B. Staten M.A. Knowler W.C. Nelson J. Vickery E.M. LeBlanc E.S. Neff L.M. Park J. Pittas A.G. Group D.d.R. Intratrial Exposure to Vitamin D and New-Onset Diabetes Among Adults With Prediabetes: A Secondary Analysis from the Vitamin D and Type 2 Diabetes (D2d) Study Diabetes Care 2020 43 2916 2922 10.2337/dc20-1765 33020052 PMC7770274
23. Favresse J. Fangazio M. Cotton F. Wolff F. Evaluation of four automated clinical analyzers for the determination of total 25(OH)D in comparison to a certified LC-MS/MS Clin. Chem. Lab. Med. 2023 61 1420 1427 10.1515/cclm-2022-1129 36785905
24. Wise S.A. Camara J.E. Sempos C.T. Lukas P. Le Goff C. Peeters S. Burdette C.Q. Nalin F. Hahm G. Durazo-Arvizu R.A. Vitamin D Standardization Program (VDSP) intralaboratory study for the assessment of 25-hydroxyvitamin D assay variability and bias J. Steroid Biochem. Mol. Biol. 2021 212 105917 10.1016/j.jsbmb.2021.105917 34010687 PMC8403635
25. Cappellani D. Brancatella A. Morganti R. Borsari S. Baldinotti F. Caligo M.A. Kaufmann M. Jones G. Marcocci C. Cetani F. Hypercalcemia due to CYP24A1 mutations: A systematic descriptive review Eur. J. Endocrinol. 2021 186 137 149 10.1530/EJE-21-0713 34735369
26. Tuckey R.C. Cheng C.Y.S. Slominski A.T. The serum vitamin D metabolome: What we know and what is still to discover J. Steroid Biochem. Mol. Biol. 2019 186 4 21 10.1016/j.jsbmb.2018.09.003 30205156 PMC6342654
27. Saponaro F. Saba A. Zucchi R. An Update on Vitamin D Metabolism Int. J. Mol. Sci. 2020 21 6573 10.3390/ijms21186573 32911795 PMC7554947
28. Vieth R. Vitamin D supplementation: Cholecalciferol, calcifediol, and calcitriol Eur. J. Clin. Nutr. 2020 74 1493 1497 10.1038/s41430-020-0697-1 32704098
Figure 1

This figure shows that 25(OH)D is “activated” by 1α-hydroxylase to calcitriol, whereas 24-hydroxylase converts 25(OH)D to 24,25(OH)2D as the first step in vitamin D catabolism. We hypothesize that the catabolism by 24-hydroxylase is reduced in individuals with high vitamin D requirements, e.g., in those with functional vitamin D deficiency.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Baseline characteristics of all study participants, stratified according to serum 25-hydroxyvitamin D in those <50 nmol/L and ≥50 nmol/L.

CharacteristicsAll (n = 505)25(OH)D < 50 nmol/L (n = 195)25(OH)D ≥ 50 nmol/L (n = 310)p Value
Females (%)52.350.753.20.591
Age (years)61.2 ± 10.659.9 ± 11.362.0 ± 10.00.026
Body mass index (kg/m2)29.6 ± 5.130.8 ± 5.728.9 ± 4.6<0.001
Office systolic BP (mm Hg)141 ± 16.6141 ± 17.1141 ± 16.30.734
Office diastolic BP (mm Hg)86.3 ± 11.086.7 ± 11.786.1 ± 10.50.573
24 h systolic BP (mm Hg)128 ± 13.9 130 ± 14.3126 ± 13.40.002
24 h diastolic BP (mm Hg)76.4 ± 9.577.5 ± 10.375.8 ± 9.00.049
NT-proBNP (pg/mL)82 (42 to 153)83 (40.8 to 150)84 (45 to 158)0.428
Corrected QT interval (ms)413 (391 to 441)414 (391 to 445)413 (391 to 439)0.865
PRC (µU/mL)17.4 (10.1 to 48.3)18.6 (10.2 to 57.5)16.9 (9.6 to 44.3)0.596
PAC (ng/dL)17.0 ± 10.316.5 ± 10.217.3 ± 10.40.39
eGFR (mL/min/1.73 m2)79.2 ± 17.781.8 ± 18.778.1 ± 16.90.021
24 h UAE (mg/24 h)8.5 (6.0 to 19.8)9.0 (6.0 to 21.0)8.0 (6.0 to 17.0)0.064
Diabetes mellitus (%)26.534.921.3<0.001
Fasting glucose (mg/dL)112 ± 40.8121 ± 49.8107 ± 33.0<0.001
HbA1c (mmol/mol)43.6 ± 11.746.2 ± 14.241.9 ± 9.4<0.001
HOMA-IR1.73 (1.03 to 3.06)2.01 (1.24 to 3.93)1.56 (0.97 to 2.76)0.005
Triglycerides (mg/dL)110 (75.0 to 154)117 (73.8 to 164)105 (75.0 to 151)0.311
HDL cholesterol (mg/dL)58.6 ± 17.357.1 ± 17.459.5 ± 17.20.142
LDL cholesterol (mg/dL)114 ± 38.4113 ± 37.9115 ± 38.70.470
PWV (m/s)8.6 ± 2.48.5 ± 2.08.6 ± 2.60.861
CRP (mg/L)1.80 (0.80 to 3.40)1.70 (0.85 to 3.40)1.9 (0.80 to 3.50)0.933
25(OH)D (nmol/L)60.4 ± 26.736.1 ± 9.675.7 ± 22.4<0.001
24,25(OH)2D (nmol/L)3.7 ± 2.61.9 ± 1.15.1 ± 2.4<0.001
VMR (%)6.2 ± 2.35.2 ± 2.46.8 ± 2.0<0.001
1,25(OH)2D (pg/mL)52.5 ± 19.844.9 ± 17.457.2 ± 19.7<0.001
Fibroblast growth factor-23 (pmol/L)0.85 (0.60 to 1.25)0.88 (0.61 to 1.37)0.83 (0.59 to 1.21)0.072
bALP (µg/L)16.9 ± 6.217.3 ± 6.916.6 ± 5.70.380
CTX (ng/mL)0.22 ± 0.180.20 ± 0.150.24 ± 0.200.058
Osteocalcin (ng/mL)14.9 ± 8.414.4 ± 8.215.3 ± 8.50.216
P1NP (ng/mL)42.0 ± 21.040.7 ± 18.342.8 ± 22.50.283
PTH (pg/mL)51.1 ± 19.556.8 ± 22.047.4 ± 16.7<0.001
Plasma calcium (mmol/L)2.38 ± 0.112.37 ± 0.112.39 ± 0.100.017
24 h UCaE (mmol/24 h)3.72 ± 2.483.59 ± 2.623.80 ± 2.390.397
Calcium supplement (%)9.95.112.90.005
Vitamin D supplement (%)10.95.114.50.001

Data are presented as means with standard deviation, medians with interquartile range or as percentages. Comparisons between the vitamin D and placebo group were calculated with Student’s t test or with Chi-Square test. BP, blood pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PRC, plasma renin concentration; PAC, plasma aldosterone concentration; eGFR, estimated Glomerular Filtration Rate; UAE, Urinary Albumin Excretion; HOMA-IR, Homeostatis Model Assessment: Insulin Resistance; PWV, pulse wave velocity; CRP, C-Reactive Protein; 25(OH)D, 25-hydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; VMR, vitamin D metabolite ratio; 1,25(OH)2D, 1,25-dihydroxyvitamin D, bALP; bone-specific alkaline phosphatase; CTX, β-CrossLaps; P1NP, procollagen type 1 amino-terminal propeptide; PTH, parathyroid hormone; UCaE, urinary calcium excretion.

Table 2

Baseline characteristics of study participants with serum 25-hydroxyvitamin D < 50 nmol/L stratified in patients with and without functional vitamin D deficiency *.

Characteristics25(OH)D < 50 nmol/L (n = 66) with Functional Deficiency25(OH)D < 50 nmol/L (n = 126) without Functional Deficiencyp Value
Females (%)50.051.20.741
Age (years)62.3 ± 10.258.7 ± 11.70.035
Body mass index (kg/m2)31.0 ± 5.830.7 ± 5.60.722
Office systolic BP (mm Hg)144 ± 18.1140 ± 16.60.187
Office diastolic BP (mm Hg)86.4 ± 11.686.9 ± 11.80.780
24 h systolic BP (mm Hg)131 ± 15.8130 ± 13.50.550
24 h diastolic BP (mm Hg)76.7 ± 9.677.9 ± 10.60.470
NT-proBNP (pg/mL)82.5 (39.0 to 171)87.5 (37.3 to 165)0.717
Corrected QT interval (ms)407 (388 to 437)416 (392 to 442)0.150
PRC (µU/mL)19.0 (12.4 to 79.3)17.4 (8.5 to 51.8)0.127
PAC (ng/dL)18.5 ± 9.415.5 ± 10.60.055
eGFR (mL/min/1.73 m2)76.5 ± 21.184.6 ± 16.80.004
24 h UAE (mg/24 h)9.0 (6.0 to 24.5)9.0 (6.0 to 21.0)0.604
Diabetes mellitus (%)54.445.6<0.001
Fasting glucose (mg/dL)141 ± 61.2110 ± 39.0<0.001
HbA1c (mmol/mol)52.6 ± 17.542.8 ± 10.8<0.001
HOMA-IR2.6 (1.5 to 5.7)2.1 (1.3 to 3.5)0.061
Triglycerides (mg/dL)117 (70.5 to 178)118 (81.8 to 150)0.504
HDL cholesterol (mg/dL)55.8 ± 20.357.8 ± 15.70.437
LDL cholesterol (mg/dL)107 ± 38.7116 ± 37.20.115
PWV (m/s)8.8 ± 2.08.4 ± 2.10.240
CRP (mg/L)1.95 (1.10 to 4.75)1.90 (0.90 to 3.40)0.017
25(OH)D (nmol/L)31.5 ± 9.738.4 ± 8.8<0.001
24,25(OH)2D (nmol/L)0.85 ± 0.462.38 ± 0.96<0.001
VMR (%)2.76 ± 0.936.43 ± 1.85<0.001
1,25(OH)2D (pg/mL)39.4 ± 18.047.7 ± 16.40.001
Fibroblast growth factor-23 (pmol/L)1.00 (0.69 to 1.44)0.89 (0.57 to 1.37)0.383
bALP (µg/L)18.1 ± 7.217.0 ± 6.70.556
CTX (ng/mL)0.19 ± 0.140.21 ± 0.150.454
Osteocalcin (ng/mL)14.0 ± 9.414.5 ± 7.50.681
P1NP (ng/mL)37.4 ± 14.442.3 ± 19.80.083
PTH (pg/mL)57.1 ± 26.756.7 ± 19.30.917
Plasma calcium (mmol/L)2.37 ± 0.112.37 ± 0.110.958
24 h UCaE (mmol/24 h)3.44 ± 2.793.67 ± 2.530.592
Calcium supplement (%)2.06.30.499
Vitamin D supplement (%)4.55.60.900

* Functional vitamin D deficiency is classified in persons with 24,25(OH)2D below 3 nmol/L and a VMR of less than 4%. Data are presented as means with standard deviation, medians with interquartile range or as percentages. Comparisons between the vitamin D and placebo group were calculated with Student’s t test or with Chi-Square test. BP, blood pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PRC, plasma renin concentration; PAC, plasma aldosterone concentration; eGFR, estimated Glomerular Filtration Rate; UAE, Urinary Albumin Excretion; HOMA-IR, Homeostatis Model Assessment: Insulin Resistance; PWV, pulse wave velocity; CRP, C-Reactive Protein; 25(OH)D, 25-hydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; VMR, vitamin D metabolite ratio; 1,25(OH)2D, 1,25-dihydroxyvitamin D; bALP, bone-specific alkaline phosphatase; CTX, β-CrossLaps; P1NP, procollagen type 1 amino-terminal propeptide; PTH, parathyroid hormone; UCaE, urinary calcium excretion.

Table 3

Parameters of mineral metabolism at baseline and follow-up, as well as changes from baseline in study participants with functional vitamin D deficiency and available values at both study visits.

CharacteristicsBaselineFollow-UpTreatment Effectp Value
25-hydroxyvitamin D (nmol/L)
     Vitamin D (n = 27)38.9 ± 14.368.8 ± 11.230.9 (24.4 to 37.5)<0.001
      Placebo (n = 22)38.9 ± 12.937.1 ± 14.0
24,25(OH)2D (nmol/L)
     Vitamin D (n = 25)1.16 ± 0.624.54 ± 1.142.6 (2.0 to 3.3)<0.001
     Placebo (n = 22)1.15 ± 0.571.88 ± 1.11
Vitamin D metabolite ratio (%)
     Vitamin D (n = 25)3.00 ± 0.956.79 ± 1.671.9 (1.1 to 2.6)<0.001
     Placebo (n = 22)3.00 ± 0.675.04 ± 1.59
1,25-dihydroxyvitamin D (pg/mL)
     Vitamin D (n = 19)50.5 ± 20.961.8 ± 27.66.2 (−7.8 to 20.1)0.377
     Placebo (n = 18)38.3 ± 17.743.3 ± 17.2
Fibroblast growth factor-23 (pmol/L)
     Vitamin D (n = 18)0.83 ± 0.712.01 ± 4.351.5 (−0.56 to 3.61)0.147
     Placebo (n = 17)1.34 ± 1.301.14 ± 0.49
Bone-specific alkaline phosphatase (µg/L)
     Vitamin D (n = 17)16.5 ± 7.616.6 ± 5.70.67 (−2.95 to 1.61)0.553
     Placebo (n = 16)19.8 ± 6.419.2 ± 6.5
β-CrossLaps (ng/mL)
     Vitamin D (n = 14)0.19 ± 0.120.18 ± 0.11−0.011 (−0.078 to 0.057)0.747
     Placebo (n = 16)0.19 ± 0.140.23 ± 0.16
Osteocalcin (ng/mL)
     Vitamin D (n = 18)12.6 ± 6.913.2 ± 5.90.46 (−2.060 to 2.986)0.711
     Placebo (n = 17)13.4 ± 6.714.4 ± 5.3
Procollagen typ 1 amino-terminal propetide (ng/mL)
     Vitamin D (n = 18)35.6 ± 17.538.5 ± 16.6−1.435 (−6.52 to 9.39)0.715
     Placebo (n = 17)40.2 ± 13.941.1 ± 11.7
Parathyroid hormone (pg/mL)#
     Vitamin D (n = 19)52.2 ± 23.446.9 ± 15.7−12.2 (−22.1 to −2.3)0.017
     Placebo (n = 20)50.9 ± 21.655.4 ± 29.6
Plasma calcium (mmol/L)
     Vitamin D (n = 19)2.38 ± 0.082.36 ± 0.07−0.008 (−0.055 to 0.040)0.747
     Placebo (n = 20)2.38 ± 0.142.37 ± 0.13
24 h urinary calcium excretion (mmol/24 h) #
     Vitamin D (n = 12)3.30 (2.10 to 7.20)3.74 (2.05 to 6.86)−0.19 (−1.34 to 1.72)0.802
     Placebo (n = 15)2.05 (1.28 to 5.40)2.53 (0.65 to 6.24)

Data at baseline and follow-up are shown as means with standard deviation or as medians with interquartile range. Treatment effects (with 95% confidence intervals) and p values were calculated by analysis of co-variance (ANCOVA) for group differences at follow-up with adjustment for baseline values; # skewed variable for which logarithmically transformed values were used in ANCOVA, but untransformed values are shown in the table.

Table 4

Cardiovascular outcome variables at baseline and follow-up and changes from baseline in study participants with functional vitamin D deficiency and available values at both study visits.

CharacteristicsBaselineFollow-UpTreatment Effectp Value
24 h systolic blood pressure (mm Hg)
     Vitamin D (n = 24)131 ± 9.5129 ± 9.3−1.14 (−6.10 to 3.83)0.647
     Placebo (n = 24)134 ± 7.4132 ± 10.6
24 h diastolic blood pressure (mm Hg)
     Vitamin D (n = 24)78.7 ± 7.676.7 ± 8.7−0.64 (−3.64 to 2.36)0.668
     Placebo (n = 24)77.8 ± 7.3 76.4 ± 8.7
N-terminal pro-B-type natriuretic peptide (ng/L) #
     Vitamin D (n = 26)45.0 (29.5 to 76.3)58.5 (35.8 to 134)2.55 (−69.5 to 74.6)0.944
     Placebo (n = 25)99.0 (45.5 to 228)98.0 (50.5 to 188)
Corrected QT interval (ms)
     Vitamin D (n = 23)409 ± 30.8422 ± 30.819.4 (−32.4 to 71.2)0.455
     Placebo (n = 24)417 ± 33.9423 ± 29.9
Plasma renin concentration (µU/mL) #
     Vitamin D (n = 24)18.3 (11.4 to 70.7)15.0 (10.6 to 47.0)−7.78 (−23.5 to 7.99)0.326
     Placebo (n = 23)14.9 (9.0 to 37.2)17.1 (8.8 to 46.7)
Plasma aldosterone concentration (ng/dL)
     Vitamin D (n = 26)16.8 ± 7.117.4 ± 6.62.53 (−1.55 to 6.62)0.218
     Placebo (n = 25)19.9 ± 10.922.8 ± 14.3
24 h urinary albumin concentration (mg/24 h) #
     Vitamin D (n = 12)7.0 (6.0 to 13.0)8.0 (7.9 to 11.9)6.99 (−14.7 to 28.7)0.509
     Placebo (n = 14)8.0 (4.0 to 120)8.0 (4.8 to 23.4)
Homeostasis Model Assessment: Insulin Resistance #
     Vitamin D (n = 26)2.38 (1.11 to 5.48)2.53 (1.38 to 4.75)0.41 (−3.1 to 3.9)0.812
     Placebo (n = 23)3.08 (1.40 to 6.80)3.79 (1.60 to 7.28)
Triglycerides (mg/dL)
     Vitamin D (n = 26)132 ± 78.0135 ± 80.82.63 (−25.2 to 30.5)0.850
     Placebo (n = 25)136 ± 72.4140 ± 64.7
HDL cholesterol (mg/dL)
     Vitamin D (n = 26)54.7 ± 15.754.9 ± 17.40.42 (−3.90 to 4.75)0.845
     Placebo (n = 25)53.2 ± 15.853.8 ± 17.2
Pulse wave velocity (m/s)
     Vitamin D (n = 23)8.68 ± 1.768.93 ± 2.320.59 (−0.57 to 1.76)0.308
     Placebo (n = 15)9.08 ± 2.588.41 ± 2.46

Data at baseline and follow-up are shown as means with standard deviation or as medians with interquartile range. Treatment effects (with 95% confidence intervals) and p values were calculated by analaysis of co-variance (ANCOVA) for group differences at follow-up with adjustment for baseline values; # skewed variable for which logarithmically transformed values were used in ANCOVA but untransformed values are shown in the table.

Publication and source details

Original title: Classification of Vitamin D Status Based on Vitamin D Metabolism: A Randomized Controlled Trial in Hypertensive Patients

Sieglinde Zelzer; Andreas Meinitzer; Dietmar Enko; Martin H. Keppel; Markus Herrmann; Verena Theiler-Schwetz; Christian Trummer; Lisa Schmitt; Andreas Tomaschitz; Patrick Sadoghi; Jutta Dierkes; Pawel Pludowski; Armin Zittermann; Winfried März; Stefan Pilz

Nutrients · 2024

* Correspondence: stefan.pilz@medunigraz.at; Tel.: +43-316-3858-1143© 2024 by the authors.2024https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Austrian National Bank1387813905The Styrian Vitamin D Hypertension Trial was supported by funding from the Austrian National Bank (Jubilaeumsfond: project Nos.: 13878 and 13905).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T04:59:50.124322+00:00

DOI: 10.3390/nu16060839 · PMC10975656